SCHEMBL22017691

SCHEMBL22017691

CC(C)n1c(=O)c2cnccc2n(C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.44
METAP2 P50579 1/20 0.40
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
ADORA2B P29275 1/20 0.38
HPD P32754 2/20 0.38
CMA1 P23946 6/20 0.37
KAT2B Q92831 2/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
TOP2A P11388 1/20 0.35
BRPF1 P55201 2/20 0.35
ATM Q13315 1/20 0.35
ATR Q13535 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22016877 0.87 ADORA3 (0.41) METAP2ADORA3ADORA2AADORA1USP2
SCHEMBL13322656 0.83 HPD (0.42) GRM4METAP2ADORA3ADORA2AADORA1
SCHEMBL13322657 0.83 MAPK14 (0.40) GRM4METAP2ADORA3ADORA2AADORA1
SCHEMBL9534299 0.83 ADORA3 (0.49) GRM4ADORA3ADORA2AADORA1HTT
SCHEMBL22016240 0.76 GRM4 (0.43) GRM4ADORA3ADORA2AADORA1HPD
SCHEMBL16352662 0.76 ERCC1 (0.61) GRM4HTTERCC1FEN1ERCC4
SCHEMBL23471345 0.75 KAT2B (0.36) GRM4METAP2ADORA3ADORA2AADORA1
SCHEMBL16640345 0.75 USP2 (0.46) METAP2USP2HTTNCOA1NCOA3
SCHEMBL22016876 0.75 AAK1 (0.40) ADORA3ADORA2AADORA1CMA1KAT2B
SCHEMBL23119826 0.74 USP2 (0.43) GRM4METAP2USP2HTTNCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 GRM4 1490/4885METAP2 3757/4885ADORA3 2207/4885
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin ITGB7, ITGB4, ITGA4 GRM4 1490/4885METAP2 3757/4885ADORA3 2207/4885
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS ITGB7, ITGB1, ITGA2B GRM4 2063/4885METAP2 3974/4885ADORA3 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.